Rhythm Phar­ma­ceu­ti­cal­s' lead drug scores in piv­otal rare obe­si­ty tri­als

Less than two years af­ter mak­ing its pub­lic de­but, Boston biotech Rhythm Phar­ma­ceu­ti­cals’ lead ex­per­i­men­tal drug has cleared two piv­otal stud­ies in pa­tients with rare, ge­net­ic obe­si­ty dis­or­ders.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER